세계의 ATP 분석 시장 규모, 점유율, 동향 분석 보고서 : 유형별, 용도별, 최종 용도별, 지역별, 부문별 예측(2025-2030년)

ATP Assays Market Size & Trends:

The global ATP assays market size was estimated at USD 3.56 billion in 2024 and is projected to grow at a CAGR of 7.91% from 2025 to 2030. This is attributed to the demand for rapid and sensitive detection methods, expanding applications in pharmaceutical and biotechnology research, regulatory approvals, and the rising burden of chronic diseases.

These drivers underscore the critical role of ATP assays in healthcare, research, and industrial sectors, facilitating advancements in personalized medicine, drug discovery, environmental monitoring, food safety and quality testing, and disease management. The 2022 WHO report highlights that food contamination affects about 600 million people globally, leading to over 200 diseases annually, including severe conditions such as diarrhea, resulting in 420,000 deaths and 33 million healthy life years lost.

The increasing prevalence of chronic diseases, such as cancer, diabetes, cardiovascular disorders, and infectious diseases, drives the demand for ATP assays in diagnostic testing and disease management. According to the report published by World Health Organization (WHO) in July 2023, 116 million people live with hepatitis B and 10 million with hepatitis C, leading to cancer, liver cirrhosis, and viral hepatitis-related deaths, and around 3 million new infections occur annually, with most going undetected in the Western Pacific Region. ATP levels are indicative of cellular dysfunction and disease progression, making these assays valuable tools for disease diagnosis, prognosis, and monitoring therapeutic responses. As healthcare systems worldwide face the challenge of managing chronic conditions, assays contribute to improving patient outcomes through early detection and personalized treatment strategies.

Contaminated food contains harmful pathogens such as bacteria, viruses, parasites, and chemical substances, posing significant health risks. ATP assays are pivotal in combating food contamination by swiftly and sensitively detecting microbial presence. These assays measure adenosine triphosphate, a universal indicator of microbial activity found in all living cells. ATP levels serve as reliable markers for assessing cleanliness in food surfaces, equipment, and processing areas. They enable prompt identification of contamination sources, empowering food manufacturers, processors, and regulators to take immediate corrective actions to prevent foodborne illnesses. In food processing, these products monitor hygiene practices, validate cleaning procedures, ensure compliance with safety standards, and enable real-time microbial monitoring to uphold food quality and safety across supply chains.

Technological innovations play a pivotal role in driving the ATP assays industry forward. Advances in assay sensitivity, accuracy, and automation have enhanced the performance and reliability of AP detection methods. Manufacturers are developing novel platforms that integrate cutting-edge technologies such as bioluminescence, fluorescence, and chemiluminescence to provide rapid and precise measurements. For instance, The RealTime-Glo Extracellular ATP Assay by Promega Corporation is a bioluminescent method designed to detect ATP released from cells undergoing stress, activation, or apoptosis. It serves as a pivotal biomarker for assessing treatments that may induce immunogenic cell death, a significant aspect of immune response modulation. These advancements cater to the growing demand for high-throughput screening and automated workflows in research laboratories and diagnostic settings.

The ATP assays industry is witnessing notable product innovation and expansion, with recent developments aimed at enhancing assay sensitivity, convenience, and affordability. A key example is Biotium's launch of the Steady-ATP HTS Viability Assay Kit in March 2025, which reflects the industry's focus on supporting high-throughput screening (HTS) applications in pharmaceutical and biotech research. The newly launched assay offers ultra-high sensitivity, detecting as few as 16 cells per well in a 384-well format, and delivers a stable luminescent signal with an extended half-life of over 5 hours. Its single-step, homogeneous workflow is designed to simplify assay protocols, making it highly compatible with automation and HTS systems. Importantly, the assay delivers performance comparable to premium market alternatives, such as CellTiter-Glo, while being positioned at a more accessible price point. This development is expected to drive broader adoption of luminescent ATP assays, particularly in budget-sensitive research laboratories and emerging biotech companies, supporting the overall growth trajectory of the ATP assays industry. Furthermore, the focus on user-friendly and cost-effective assays aligns with the market's shift toward enabling real-time, scalable, and high-efficiency cell viability and metabolic studies across various research and quality testing domains.

Global ATP Assays Market Report Segmentation

This report forecasts revenue growth and provides an analysis on the latest trends in each of the sub-segments from 2018 to 2030. For this report, Grand View Research has segmented the global ATP assays market report based on type, application, end use, and region:

• Type Outlook (Revenue, USD Million, 2018 - 2030)
• Luminometric ATP Assays
• Enzymatic ATP Assays
• Bioluminescence Resonance Energy Transfer (BRET) ATP Assays
• Cell-based ATP Assays
• Others
• Application Outlook (Revenue, USD Million, 2018 - 2030)
• Drug Discovery & Development
• Clinical Diagnostics
• Environmental Testing
• Food Safety & Quality Testing
• Others
• End Use Outlook (Revenue, USD Million, 2018 - 2030)
• Pharmaceutical & Biotechnology Companies
• Academic & Research Institutes
• Hospital & Diagnostics Laboratories
• Regional Outlook (Revenue, USD Million, 2018 - 2030)
• North America
  • U.S.
  • Canada
  • Mexico
• Europe
  • UK
  • Norway
  • Sweden
  • Denmark
  • Spain
  • Italy
  • France
  • Germany
• Asia Pacific
  • Japan
  • China
  • India
  • South Korea
  • Australia
  • Thailand
• Latin America
  • Brazil
  • Argentina
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE
  • Kuwait

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
  • 1.2.1. Type
  • 1.2.2. Application
  • 1.2.3. End Use
  • 1.2.4. Regional scope
  • 1.2.5. Estimates and forecasts timeline
• 1.3. Research Methodology
• 1.4. Information Procurement
  • 1.4.1. Purchased database
  • 1.4.2. GVR's internal database
  • 1.4.3. Secondary sources
  • 1.4.4. Primary research
  • 1.4.5. Details of primary research
    • 1.4.5.1. Data for primary interviews in North America
    • 1.4.5.2. Data for primary interviews in Europe
    • 1.4.5.3. Data for primary interviews in Asia Pacific
    • 1.4.5.4. Data for primary interviews in Latin America
    • 1.4.5.5. Data for Primary interviews in MEA
• 1.5. Information or Data Analysis
  • 1.5.1. Data analysis models
• 1.6. Market Formulation & Validation
• 1.7. Model Details
  • 1.7.1. Commodity flow analysis (Model 1)
  • 1.7.2. Approach 1: Commodity flow approach
  • 1.7.3. Volume price analysis (Model 2)
  • 1.7.4. Approach 2: Volume price analysis
• 1.8. List of Secondary Sources
• 1.9. List of Primary Sources

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
  • 2.2.1. Type outlook
  • 2.2.2. Application Outlook
  • 2.2.3. End Use Outlook
  • 2.2.4. Regional outlook
• 2.3. Competitive Insights

Chapter 3. ATP Assays Market Variables, Trends, & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent Market Outlook
  • 3.1.2. Ancillary Market Outlook
• 3.2. Market Dynamics
  • 3.2.1. Market Driver Analysis
  • 3.2.2. Market Restraint Analysis
  • 3.2.3. Industry Analysis - Porter's
    • 3.2.3.1. Bargaining power of the suppliers
    • 3.2.3.2. Bargaining power of the buyers
    • 3.2.3.3. Threats of substitution
    • 3.2.3.4. Threats from new entrants
    • 3.2.3.5. Competitive rivalry
  • 3.2.4. PESTEL Analysis
    • 3.2.4.1. Political landscape
    • 3.2.4.2. Economic and Social landscape
    • 3.2.4.3. Technological landscape
• 3.3. Impact of COVID 19 on ATP Assays market
• 3.4. Pricing Analysis, at Regional Level
  • 3.4.1. North America
  • 3.4.2. Europe
  • 3.4.3. Asia Pacific
  • 3.4.4. Latin America
  • 3.4.5. MEA

Chapter 4. ATP Assays Market: Type Estimates & Trend Analysis

• 4.1. Segment Dashboard
• 4.2. ATP Assays Market: Type Movement Analysis, 2024 & 2030 (USD Million)
  • 4.2.1. Luminometric ATP Assays
    • 4.2.1.1. Luminometric ATP Assays Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 4.2.2. Enzymatic ATP Assays
    • 4.2.2.1. Enzymatic ATP Assays Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 4.2.3. Cell-based ATP Assays
    • 4.2.3.1. Cell-based ATP Assays Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 4.2.4. Others
    • 4.2.4.1. Other Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 4.2.5. Graspers/ Clips

Chapter 5. ATP Assays Market: Application Estimates & Trend Analysis

• 5.1. Segment Dashboard
• 5.2. ATP Assays Market: Application Movement Analysis, 2024 & 2030 (USD Million)
  • 5.2.1. Drug Discovery and Development
    • 5.2.1.1. Drug Discovery and Development Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 5.2.2. Clinical Diagnostics
    • 5.2.2.1. Clinical Diagnostics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.2.3. Environmental Testing
    • 5.2.3.1. Environmental Testing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.2.4. Food Safety and Quality Testing
    • 5.2.4.1. Food Safety and Quality Testing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.2.5. Others
    • 5.2.5.1. Other Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 6. ATP Assays Market: End Use Estimates & Trend Analysis

• 6.1. Segment Dashboard
• 6.2. ATP Assays Market: End Use Movement Analysis, 2024 & 2030 (USD Million)
  • 6.2.1. Pharmaceutical and Biotechnology Companies
    • 6.2.1.1. Pharmaceutical and Biotechnology Companies Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.2.2. Academic and Research Institutes
    • 6.2.2.1. Academic and Research Institutes Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.2.3. Hospital and Diagnostics Laboratories
    • 6.2.3.1. Hospital and Diagnostics Laboratories Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 7. ATP Assays Market: Regional Estimates & Trend Analysis

• 7.1. Regional Market Share Analysis, 2024 & 2030
• 7.2. Regional Market Dashboard
• 7.3. Global Regional Market Snapshot
• 7.4. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
• 7.5. North America
  • 7.5.1. U.S.
    • 7.5.1.1. Key country dynamics
    • 7.5.1.2. Regulatory framework/ reimbursement structure
    • 7.5.1.3. Competitive scenario
    • 7.5.1.4. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.5.2. Canada
    • 7.5.2.1. Key country dynamics
    • 7.5.2.2. Regulatory framework/ reimbursement structure
    • 7.5.2.3. Competitive scenario
    • 7.5.2.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.5.3. Mexico
    • 7.5.3.1. Key country dynamics
    • 7.5.3.2. Regulatory framework/ reimbursement structure
    • 7.5.3.3. Competitive scenario
    • 7.5.3.4. Mexico market estimates and forecasts 2018 to 2030 (USD Million)
• 7.6. Europe
  • 7.6.1. UK
    • 7.6.1.1. Key country dynamics
    • 7.6.1.2. Regulatory framework/ reimbursement structure
    • 7.6.1.3. Competitive scenario
    • 7.6.1.4. UK market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.6.2. Germany
    • 7.6.2.1. Key country dynamics
    • 7.6.2.2. Regulatory framework/ reimbursement structure
    • 7.6.2.3. Competitive scenario
    • 7.6.2.4. Germany market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.6.3. France
    • 7.6.3.1. Key country dynamics
    • 7.6.3.2. Regulatory framework/ reimbursement structure
    • 7.6.3.3. Competitive scenario
    • 7.6.3.4. France market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.6.4. Italy
    • 7.6.4.1. Key country dynamics
    • 7.6.4.2. Regulatory framework/ reimbursement structure
    • 7.6.4.3. Competitive scenario
    • 7.6.4.4. Italy market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.6.5. Spain
    • 7.6.5.1. Key country dynamics
    • 7.6.5.2. Regulatory framework/ reimbursement structure
    • 7.6.5.3. Competitive scenario
    • 7.6.5.4. Spain market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.6.6. Norway
    • 7.6.6.1. Key country dynamics
    • 7.6.6.2. Regulatory framework/ reimbursement structure
    • 7.6.6.3. Competitive scenario
    • 7.6.6.4. Norway market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.6.7. Sweden
    • 7.6.7.1. Key country dynamics
    • 7.6.7.2. Regulatory framework/ reimbursement structure
    • 7.6.7.3. Competitive scenario
    • 7.6.7.4. Sweden market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.6.8. Denmark
    • 7.6.8.1. Key country dynamics
    • 7.6.8.2. Regulatory framework/ reimbursement structure
    • 7.6.8.3. Competitive scenario
    • 7.6.8.4. Denmark market estimates and forecasts 2018 to 2030 (USD Million)
• 7.7. Asia Pacific
  • 7.7.1. Japan
    • 7.7.1.1. Key country dynamics
    • 7.7.1.2. Regulatory framework/ reimbursement structure
    • 7.7.1.3. Competitive scenario
    • 7.7.1.4. Japan market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.7.2. China
    • 7.7.2.1. Key country dynamics
    • 7.7.2.2. Regulatory framework/ reimbursement structure
    • 7.7.2.3. Competitive scenario
    • 7.7.2.4. China market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.7.3. India
    • 7.7.3.1. Key country dynamics
    • 7.7.3.2. Regulatory framework/ reimbursement structure
    • 7.7.3.3. Competitive scenario
    • 7.7.3.4. India market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.7.4. Australia
    • 7.7.4.1. Key country dynamics
    • 7.7.4.2. Regulatory framework/ reimbursement structure
    • 7.7.4.3. Competitive scenario
    • 7.7.4.4. Australia market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.7.5. South Korea
    • 7.7.5.1. Key country dynamics
    • 7.7.5.2. Regulatory framework/ reimbursement structure
    • 7.7.5.3. Competitive scenario
    • 7.7.5.4. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.7.6. Thailand
    • 7.7.6.1. Key country dynamics
    • 7.7.6.2. Regulatory framework/ reimbursement structure
    • 7.7.6.3. Competitive scenario
    • 7.7.6.4. Thailand market estimates and forecasts 2018 to 2030 (USD Million)
• 7.8. Latin America
  • 7.8.1. Brazil
    • 7.8.1.1. Key country dynamics
    • 7.8.1.2. Regulatory framework/ reimbursement structure
    • 7.8.1.3. Competitive scenario
    • 7.8.1.4. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.8.2. Argentina
    • 7.8.2.1. Key country dynamics
    • 7.8.2.2. Regulatory framework/ reimbursement structure
    • 7.8.2.3. Competitive scenario
    • 7.8.2.4. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
• 7.9. MEA
  • 7.9.1. South Africa
    • 7.9.1.1. Key country dynamics
    • 7.9.1.2. Regulatory framework/ reimbursement structure
    • 7.9.1.3. Competitive scenario
    • 7.9.1.4. South Africa market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.9.2. Saudi Arabia
    • 7.9.2.1. Key country dynamics
    • 7.9.2.2. Regulatory framework/ reimbursement structure
    • 7.9.2.3. Competitive scenario
    • 7.9.2.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.9.3. UAE
    • 7.9.3.1. Key country dynamics
    • 7.9.3.2. Regulatory framework/ reimbursement structure
    • 7.9.3.3. Competitive scenario
    • 7.9.3.4. UAE market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.9.4. Kuwait
    • 7.9.4.1. Key country dynamics
    • 7.9.4.2. Regulatory framework/ reimbursement structure
    • 7.9.4.3. Competitive scenario
    • 7.9.4.4. Kuwait market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 8. Competitive Landscape

• 8.1. Recent Developments & Impact Analysis, By Key Market Participants
• 8.2. Company/Competition Categorization
• 8.3. Vendor Landscape
  • 8.3.1. Key company market share analysis, 2024
  • 8.3.2. Thermo Fisher Scientific
    • 8.3.2.1. Company overview
    • 8.3.2.2. Financial performance
    • 8.3.2.3. Type benchmarking
    • 8.3.2.4. Strategic initiatives
  • 8.3.3. Promega Corporation
    • 8.3.3.1. Company overview
    • 8.3.3.2. Financial performance
    • 8.3.3.3. Type benchmarking
    • 8.3.3.4. Strategic initiatives
  • 8.3.4. PerkinElmer Inc.
    • 8.3.4.1. Company overview
    • 8.3.4.2. Financial performance
    • 8.3.4.3. Type benchmarking
    • 8.3.4.4. Strategic initiatives
  • 8.3.5. Becton, Dickinson and Company (BD)
    • 8.3.5.1. Company overview
    • 8.3.5.2. Financial performance
    • 8.3.5.3. Type benchmarking
    • 8.3.5.4. Strategic initiatives
  • 8.3.6. Lonza Group Ltd.
    • 8.3.6.1. Company overview
    • 8.3.6.2. Financial performance
    • 8.3.6.3. Type benchmarking
    • 8.3.6.4. Strategic initiatives
  • 8.3.7. Danaher Corporation
    • 8.3.7.1. Company overview
    • 8.3.7.2. Financial performance
    • 8.3.7.3. Type benchmarking
    • 8.3.7.4. Strategic initiatives
  • 8.3.8. Abcam plc
    • 8.3.8.1. Company overview
    • 8.3.8.2. Financial performance
    • 8.3.8.3. Type benchmarking
    • 8.3.8.4. Strategic initiatives
  • 8.3.9. Quest Diagnostics Incorporated
    • 8.3.9.1. Company overview
    • 8.3.9.2. Financial performance
    • 8.3.9.3. Type benchmarking
    • 8.3.9.4. Strategic initiatives
  • 8.3.10. Biomerieux SA
    • 8.3.10.1. Company overview
    • 8.3.10.2. Financial performance
    • 8.3.10.3. Type benchmarking
    • 8.3.10.4. Strategic initiatives
  • 8.3.11. 3M Company
    • 8.3.11.1. Company overview
    • 8.3.11.2. Financial performance
    • 8.3.11.3. Type benchmarking
    • 8.3.11.4. Strategic initiatives